Strs Ohio Has $916,000 Holdings in Veracyte, Inc. (NASDAQ:VCYT)

Strs Ohio trimmed its holdings in shares of Veracyte, Inc. (NASDAQ:VCYT) by 4.0% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 33,300 shares of the biotechnology company’s stock after selling 1,400 shares during the period. Strs Ohio’s holdings in Veracyte were worth $916,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the stock. Jennison Associates LLC acquired a new position in shares of Veracyte during the 3rd quarter valued at about $9,324,000. AEGON ASSET MANAGEMENT UK Plc acquired a new position in Veracyte during the fourth quarter valued at approximately $9,586,000. Northern Trust Corp raised its position in shares of Veracyte by 38.0% in the third quarter. Northern Trust Corp now owns 982,328 shares of the biotechnology company’s stock valued at $21,935,000 after purchasing an additional 270,531 shares during the period. Invesco Ltd. lifted its stake in shares of Veracyte by 38.5% in the third quarter. Invesco Ltd. now owns 476,349 shares of the biotechnology company’s stock worth $10,637,000 after buying an additional 132,310 shares during the last quarter. Finally, QRG Capital Management Inc. bought a new stake in shares of Veracyte during the 3rd quarter worth $2,843,000.

Insider Transactions at Veracyte

In related news, Director Karin Eastham sold 10,000 shares of the company’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $21.65, for a total transaction of $216,500.00. Following the transaction, the director now owns 33,125 shares in the company, valued at approximately $717,156.25. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 2.60% of the company’s stock.

Veracyte Stock Up 0.4 %

VCYT opened at $19.90 on Thursday. Veracyte, Inc. has a twelve month low of $18.61 and a twelve month high of $30.52. The firm’s 50-day simple moving average is $21.82 and its 200-day simple moving average is $23.91.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.03. Veracyte had a negative net margin of 20.61% and a negative return on equity of 2.02%. The firm had revenue of $98.20 million for the quarter, compared to analysts’ expectations of $95.49 million. Equities analysts expect that Veracyte, Inc. will post -0.29 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently commented on the stock. The Goldman Sachs Group dropped their target price on shares of Veracyte from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Monday, April 15th. Needham & Company LLC boosted their price objective on Veracyte from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, February 23rd. William Blair reaffirmed an “outperform” rating on shares of Veracyte in a report on Friday, February 23rd. Finally, Morgan Stanley lowered their price objective on shares of Veracyte from $22.00 to $21.00 and set an “underweight” rating on the stock in a research note on Monday, February 26th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $29.00.

Veracyte Company Profile

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.